Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 219

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Alteration of Topoisomerase II–Alpha Gene in Human Breast Cancer: Association With Responsiveness to Anthracycline-Based Chemotherapy

Open access
Press, Michael F., Sauter, Guido, Buyse, Marc, Bernstein, Leslie, Guzman, Roberta, Santiago, Angela, Villalobos, Ivonne E., Eiermann, Wolfgang, Pienkowski, Tadeusz, Martin, Miguel, Robert, Nicholas, Crown, John, Bee, Valerie, Taupin, Henry, Flom, Kerry J., Tabah-Fisch, Isabelle, Pauletti, Giovanni, Lindsay, Mary-Ann, Riva, Alessandro, Slamon, Dennis J.·2011·Journal of Clinical Oncology

Abstract

Purpose: Approximately 35% of HER2-amplified breast cancers have coamplification of the topoisomerase II-alpha (TOP2A) gene encoding an enzyme that is a major target of anthracyclines. This study was designed to evaluate whether TOP2A gene alterations may predict incremental responsiveness to anthracyclines in some breast cancers. Methods: A total of 4,943 breast cancers were analyzed for alterations in TOP2A and HER2. Primary tumor tissues from patients with metastatic breast cancer treated in a trial of chemotherapy plus/minus trastuzumab were studied for amplification/deletion of TOP2A and HER2 as a test set followed by evaluation of malignancies from two separate, large trials for changes in these same genes as a validation set. Association between these alterations and clinical outcomes was determined. Results: Test set cases containing HER2 amplification treated with doxorubicin and cyclophosphamide (AC) plus trastuzumab, demonstrated longer progression-free survival compared to those treated with AC alone (P = .0002). However, patients treated with AC alone whose tumors contain HER2/TOP2A coamplification experienced a similar improvement in survival (P = .004). Conversely, for patients treated with paclitaxel, HER2/TOP2A coamplification was not associated with improved outcomes. These observations were confirmed in a larger validation set, where HER2/TOP2A coamplification was again associated with longer survival when only anthracycline-containing chemotherapy was used for treatment compared with outcome in HER2-positive cancers lacking TOP2A coamplification. Conclusion: In a study involving nearly 5,000 breast malignancies, both test set and validation set demonstrate that TOP2A coamplification, not HER2 amplification, is the clinically useful predictive marker of an incremental response to anthracycline-based chemotherapy. Absence of HER2/TOP2A coamplification may indicate a more restricted efficacy advantage for breast cancers than previously thought.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2009.27.5644

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 219

Metadata

Authors
Press, M. F., Sauter, G., Buyse, M., Bernstein, L., Guzman, R., Santiago, A., Villalobos, I. E., Eiermann, W., Pienkowski, T., Martin, M., Robert, N., Crown, J., Bee, V., Taupin, H., Flom, K. J., Tabah-Fisch, I., Pauletti, G., Lindsay, M.-A., Riva, A., & Slamon, D. J.
Venue
Journal of Clinical Oncology
Published
2011-03-01
Volume
29
Issue
7
Pages
859-867
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2167341447
Cited by
219
References
1
FWCI
10.26
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Alteration of Topoisomerase II–Alpha Gene in Human Breast Cancer: Association With Responsiveness to Anthracycline-Based Chemotherapy. https://app.cochat.ai/papers/10.1200/jco.2009.27.5644
The paper
Press, M. F., Sauter, G., Buyse, M., Bernstein, L., Guzman, R., Santiago, A., Villalobos, I. E., Eiermann, W., Pienkowski, T., Martin, M., Robert, N., Crown, J., Bee, V., Taupin, H., Flom, K. J., Tabah-Fisch, I., Pauletti, G., Lindsay, M.-A., Riva, A., & Slamon, D. J. (2011). Alteration of Topoisomerase II–Alpha Gene in Human Breast Cancer: Association With Responsiveness to Anthracycline-Based Chemotherapy. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2009.27.5644

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.